Needham Maintains Buy on Vaxcyte, Raises Price Target to $122
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $110 to $122.
Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $110 to $122.